CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
1. CAMP4 secures $100 million funding for SYNGAP1 clinical trials. 2. Initial financing includes $50 million upfront and $50 million based on milestones. 3. Doug Williams appointed Board Chair amidst significant management changes. 4. CAMP4 aims to develop first-in-class treatments for genetic disorders. 5. Private placement financing indicates strong investor confidence in CAMP4's future.